NCT05835167Not yet recruiting

Complete Revascularization Via Inferior Part-sternotomy

Minimally Invasive Coronary Artery Bypass Grafting Achieving Complete Revascularization of Multivessel Coronary Artery Disease Via Inferior Part-Sternotomy (The ACRIS-MICABG Trial)

Source: ClinicalTrials.gov · Last updated 28 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.

Status (registry): Not yet recruiting
Study type: Interventional
Enrollment: 260 (estimated)
First submitted: 16 Apr 2023
Start date: 5 May 2023
Primary completion date: 4 May 2025
Lead sponsor: China National Center for Cardiovascular Diseases
Diseases: Coronary artery disease
NCT number: NCT05835167

What you commit to

Study type: Interventional
Planned participants: 260
From 5 May 2023 to the primary completion date, 4 May 2025
No sites listed in no country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).
Subjects tend to choose surgical approach (via full median sternotomy/inferior part-sternotomy) .

Other illness

Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.
Malignant tumor or other severe systemic diseases.
Contraindications for dual antiplatelet therapy, such as active gastroduodenal ulcer.

Lab values

Left ventricular ejection fraction(EF≤35%).
Severe renal insufficiency (i.e. creatinine \>200 μmol/L).

Other

Redo CABG.
Emergent CABG.
Severe atherosclerosis of the ascending aorta.
Participant of other ongoing clinical trials.

Who the study is looking for

Patients who undergo primary isolated open-chest CABG with multi-vessel coronary disease(left main artery disease with right coronary artery disease,or three-vessel disease)

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Related publications

Achieving completed revascularization via inferior mini-sternotomy versus conventional median sternotomy for CABG in patients with multivessel CAD (the ACRIS-MICABG trial): Rationale and design of a multicentre, randomized controlled trial.Contemp Clin Trials · 2026 · PMID 42276410

This page is information, not medical advice. Discuss any trial with your doctor.